Side-by-side comparison of AI visibility scores, market position, and capabilities
1M+ clinicians 150+ countries; 250K active providers; $50.2M revenue; acquired Telehealth.org/TeleMental Health Institute 2025; TIME HealthTech 2025; Ventures fund; telemedicine leader
Doxy.me was founded in 2013 by Brandon Welch in Hawaii with a mission to make telehealth accessible to every clinician and patient, regardless of technical sophistication or budget. The platform was built as a browser-based, zero-download video conferencing solution designed specifically for healthcare — requiring no app installation for patients and offering HIPAA-compliant video sessions out of the box. This simplicity-first approach drove grassroots adoption among solo practitioners and small clinics.\n\nDoxy.me's platform provides HIPAA-compliant video visits, virtual waiting rooms, patient intake forms, group rooms, and integrations with major EHR and practice management systems. Its free tier has been instrumental in driving adoption among independent clinicians who need compliant telehealth without enterprise procurement cycles. Premium tiers add advanced features including custom branding, staff accounts, and analytics. In 2025, Doxy.me acquired Telehealth.org and the TeleMental Health Institute, expanding its educational resources and professional training offerings.\n\nDoxy.me has grown to serve 1M+ clinicians across 150+ countries, with 250,000 active providers using the platform regularly. The company reported $50.2M in annual revenue and was recognized on TIME's HealthTech 2025 list. Its combination of clinical accessibility, global reach, and a freemium model that converts at scale positions Doxy.me as a foundational layer of the global telehealth infrastructure — particularly for solo and small-group practices that larger enterprise platforms overlook.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.